Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Cash from Financing Activities (2021 - 2025)

Prime Medicine filings provide 5 years of Cash from Financing Activities readings, the most recent being $562000.0 for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 56100.0% to $562000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $151.5 million, a 22.65% decrease, with the full-year FY2025 number at $151.5 million, down 22.65% from a year prior.
  • Cash from Financing Activities hit $562000.0 in Q4 2025 for Prime Medicine, down from $144.8 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $184.1 million in Q4 2022 to a low of -$1.3 million in Q1 2022.
  • Median Cash from Financing Activities over the past 5 years was $194000.0 (2023), compared with a mean of $31.1 million.
  • Biggest five-year swings in Cash from Financing Activities: plummeted 99.89% in 2023 and later surged 231263.24% in 2024.
  • Prime Medicine's Cash from Financing Activities stood at -$1.1 million in 2021, then surged by 17049.63% to $184.1 million in 2022, then plummeted by 99.89% to $194000.0 in 2023, then crashed by 99.48% to $1000.0 in 2024, then surged by 56100.0% to $562000.0 in 2025.
  • The last three reported values for Cash from Financing Activities were $562000.0 (Q4 2025), $144.8 million (Q3 2025), and $197000.0 (Q2 2025) per Business Quant data.